soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 Semaglutide and Cardiovascular Outcomes in

The estimate of liver necrosis is rather small, less that 0.05% damage, and this may be sufficient to account for the elevation of ALT observed by Watkins et al.[38], and the absence of symptoms of liver disease after chronic usage

Sleep deprivation increases ghrelin (hunger hormone) production and decreases leptin (satiety hormone), effectively counteracting tirzepatide's effects

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease

In a shift towards functional bioactive molecules, more recent peptidomic studies in A

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut

"Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)"